中文部份
台灣血液透析診療指引。台灣腎臟醫學會編著,民國93年12月30日。
健保醫字第0900015412號,全民健康保險藥品給付規定修正規定,造血功能治療藥物-紅血球生成素,90年6月21日。
健保審字第0930006236號,全民健康保險藥品給付規定修正規定,4.1.造血功能治療藥物,93年4月15日。
健保審字第 0930021060 號,修正「全民健康保險藥品給付規定」:代謝及營養劑,民國 93 年 11 月 15 日。
健保藥字第0950070568號,全民健康保險藥品給付規定修正規定,4.1.造血功能治療藥物,95年9月22日。
楊五常,透析服務支付政策之評估,行政院衛生署101年度委託研究計畫研究成果期末報告,101年12月。
96年第四季門診透析總額品質報告,指標5.10 (94Q1 96Q4);http://www.nhi.gov.tw/webdata/webdata.aspx?menu=17&menu_id=1027&WD_ID=1035&webdata_id=818
99年第三季門診透析總額品質報告,指標5.12 (97Q1 to 99Q3)http://www.nhi.gov.tw/webdata/webdata.aspx?menu=17&menu_id=1027&WD_ID=1035&webdata_id=818
謝其政 (2011)。台灣末期腎臟病患血液透析與腹膜透析成本效果分析。國立台灣大學公共衛生學院健康政策與管理研究所博士論文。蔡雅馨 (2011)。門診透析總額制度對末期腎臟病患醫療利用與處方藥品之影響。國立台灣大學公共衛生學院健康政策與管理研究所碩士論文。張宏瑋 (2011)。台灣2020年末期腎臟病透析治療發生人數與盛行人數預測。國立台灣大學公共衛生學院健康政策與管理研究所碩士論文。英文部份
AranespUS FDA label, 17 Dec 2007 version.
AranespUS FDA label, 24June 2011 version.
Besarab A, Bolton WK, Browne JK, Egrie JC, et al.(1998). The effect of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. The New England Journal of Medicine, 339:584-90.
Brenner & Rector’s The Kidney. 2012
KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease:2007 Update of Hemoglobin Target. (2007). American Journal of Kidney Disease, 50(3):477-512.
Epogen US FDA label, 17 Dec 2007 version.
Epogen US FDA label, 24 June 2011 version.
Eschbach JW, Abdulhadi MH, Browne JK, et al.(1989) Recombinant human erythropoietin in anemic patients with end-stage renal disease: results of a phase III multicenter clinical trial. Ann Intern Med, 111:992-1000.
European Medical Agency (EMA). Public Statement (2007)Epoetins and the risk of tumor growth progression and thromboembolic events in cancer patients and cardiovascular risks in patients with chronic kidney disease.Doc.Ref. EMEA/496188/2007
Evans RW, Rader B, Manninen DL (1990) Cooperative Multicenter EPO Clinical Trial Group. The quality of life of hemodialysis recipients treated with recombinant human erythropoietin. JAMA, 263:825-830.
Fishbane S, Besarb A (2007) Mechanism of increased mortality risk with erythropoietn treatment to higher hemoglobin targets. Clin J Am Soc Nephro, 2:1274-1282
Kaufman JS (2011) Relationship of erythropoiesis-stimulating agent dose and reponsiveness and adverse outcomes in CKD. Am J Kidney Dis, 57(5):661-663
Mircera US FDA label, 14 Nov 2007 version.
Mircera EMA label, 19 June 2012 version.
Pfeffer MA, Burdmann EA, Chen CY, et al. (2010). A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. The New England Journal of Medicine, 361:2019-32.
Procrit US FDA label, 17 Dec 2007 version.
Procrit US FDA label, 24 June 2011 version.
Schrier RW.: Diseases of the Kidney and Urinary Tract. Lippincott Williams & Xilkins. 2001.
Singh AK, Szczech L, Tang KL, et al. (2006) Correction of anemia with epoetin alfa in chronic kidney disease.The New England Journal of Medicine, 355:2085-98.
Singh AK, Himmelfarb J, Szczech LA (2009) Resolved: Targeting a higher hemoglobin is associated with greater risk in patients with CKD anemia. J Am Soc Nephrol, 20:1436-1443
Singh AK (2010) Dose TREAT give the boot to ESAs in the treatment of CKD anemia? J Am Soc Nephrol,1-13 21:
Solomon SD, Uno H, Lewis EF, et al. (2010) Erythropoietin Response and outcomes in kidney disease and type 2 diabetes. N Engl J Med, 363(12):1146-1155.
Szczech L, Barnhart HX, Inrig JK, Reddan DN, et al. (2008) Secondary analysis of the CHOIR trial epoetin-α dose and achieved hemoglobin outcomes. Kidney International, 74:791-798
Macdougall IC, Lewis NP, Saunders MJ, et al. (1990)Long-term cardiorespiratory effects of amelioration of renal anemia by erythropoietin. Lancet, 335:489-493[Erratum, Lancet 1990; 335:614]
US Food and Drug Administration (FDA) Safety Announcement (2011) FDA Drug Safty Communication: Modified dosing recommendations to improve the safe use of Erythropoiesis-Stimulating Agenst (ESAs) in chronic kidney disease. 24 June.
U.S. Renal Data System. (2012). USRDS 2012 annual data report: Atlas of end-stage renal disease in the United States.
World Health Organization (2011) Hemoglobin concnetrations for the diagnosis of anemia and assessment of severity. WHO/NMH/NHD/MNM/11.1